Immunomedics Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research

        Print
| Source: Immunomedics, Inc.

MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that six posters will be presented at the 2013 Annual Meeting of the American Association for Cancer Research to be held in Washington, DC, from April 6 – 10, 2013.

The schedule and meeting places for the poster sessions, together with the abstract number, poster section and poster board numbers, are listed below:

  • "MAb-PAM4 can differentiate between pancreatic ductal adenocarcinoma and chronic pancreatitis" [Abstract No. 1141, Session Title: Biomarkers 2: Gastrointestinal Cancers, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 1, Poster Board Number 3]
     
  • "Targeting interferon-Lambda 1 with a stabilized dimer of anti-tumor Fab" [Abstract No. 1221, Session Title: Cytokines, Modification of the Tumor Microenvironment, and Intervention, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 1]
     
  • "Cell-cell fusion in vivo transfers genes for human malignancy, metastasis, and the donor tumors' organoid phenotype to stromal hamster cells" [Abstract No. 1630, Session Title: Tumor-Stromal Interactions, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 21, Poster Board Number 8]
     
  • "A Phase I study of IMMU-130 (labetuzumab-SN-38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC)" [Abstract No. LB-159, Session Title: Late-Breaking Research: Clinical Trials, Tuesday, April 9, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 47]
     
  • "CD22-targeting epratuzumab mediates trogocytosis of multiple cell-surface markers on normal, malignant, and lupus B cells" [Abstract No. 4744, Session Title: Immune Therapeutics and Monoclonal Antibodies 2, Wednesday, April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 13]
     
  • "Novel T-cell redirecting trivalent bispecific antibodies" [Abstract No. 4747, Session Title: Immune Therapeutics and Monoclonal Antibodies 2, Wednesday, April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 16]

Cynthia L. Sullivan, President and CEO, commented: "Our presentations represent a diverse set of products and technologies for the therapy of hematological and solid cancers, including our elucidation of the possible mechanism of action of epratuzumab in the therapy of system lupus erythematosus. The late-breaking poster on our IMMU-130 product candidate will present our first clinical results with this novel antibody-drug conjugate in patients with advanced, relapsed, metastatic colorectal cancers from our ongoing Phase I dose-escalation trial."

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 219 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at http://www.immunomedics.com/ blocked::http://www.immunomedics.com/">www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:
Dr. Chau Cheng
Senior Director, Investor Relations & Grant Management
(973) 605-8200, extension 123